Emergency contraception can be used after intercourse to stop before the pregnancy starts. There are two main types of emergency contraceptives: emergency contraceptive pills (ECPs) and copper tea intrauterine devices (IUDs). Some reproductive techniques are being developed, counting artificial insemination, germ selection techniques, in vitro parthenogenesis, and reprogenetics.
The global human reproductive technologies market is estimated to account for US$ 28,426.7 Mn in 2019 in terms of value and US$ 34,228.3 Mn by the end of 2027.
Get Free Sample PDF Copy (Including Full TOC, List of Tables & Figures, Chart) @
https://www.coherentmarketinsights.com/insight/request-sample/3921
The high rate of infertility is likely to drive growth in the global human reproductive technologies market over the estimated period. For example, according to the National Survey of Family Growth Data published in September 2018, in the US, 15.5% of women who want to become pregnant are infertile and 6.7% of married women between the ages of 15 and 44 are infertile.
Global Human Reproductive Technologies Market: Opportunities
Research and development in the diagnosis of infertility is likely to provide beneficial growth opportunities for players in the global human reproductive technologies market. For example, DiaSorin S.p.A launched the LIAISON test in May 2018 to measure sex hormone-binding globulin in human serum and plasma for the diagnosis of infertility, libido and erectile dysfunction in men, and polycystic ovary syndrome in women.
Side effects related to the use of contraceptives and devices are likely to obstruct market growth. Long-term side effects related to oral contraceptive pills, like as breast cancer, blood clots, and an increased risk of heart disease, are strongly discouraged.
The size of the global human reproductive technologies market was estimated to be accounted at US$ 28,426.7 Million and over the estimated market (2020-2027) it is estimated to witness a value of US$ 34,228.3 Million with a CAGR of 2.4%. Key aspects driving the growth of the global human reproductive technologies market during the estimated period count the increasing maternal mortality rate and the growing population and focus on family planning.
In 2019, North America led the global human reproductive technologies market, considering 46.1% in value, then Europe and Asia Pacific, sequentially. The growing population’s preference for the use of human reproductive technology in the region is likely to support market growth.
Initiatives to raise awareness about human reproductive technologies are likely to drive market growth. For example, Cryos USA, the US-based sperm and egg bank, held a scientific seminar on auxiliary reproductive technology (ART) in February 2020.
The use of machine learning and artificial intelligence (AI) to diagnose infertility is on the rise. Researchers at Peking University, China, for example, proposed in May 2020 a special convoluted neural network architecture for accurate classification of human sperm heads based on sperm images.
January 2020: Bayer Healthcare AG signs a licensing agreement with Daré Bioscience, Inc., a provider of products for women’s health, under which Bayer can commercialize Daré’s investigative contraceptive product, Ovaprene, in the US once approved by the USFDA.
May 2020: Ferring Pharmaceuticals announces that Menotropin is a comparable to Menotropin for the development of multiple follicles and injections indicated for pregnancy in menopausal-assisted reproductive technology (ART) programs. Endpoint, menopausal-treated patients begin 35.5% OPR per cycle after a new transfer.
Request PDF Brochure with Latest Insights @
https://www.coherentmarketinsights.com/insight/request-pdf/3921
Competitive Landscape
Key players performing in the global human reproductive technologies are Merck Serono, Daré Bioscience Inc., Johnson & Johnson, Ferring Pharmaceuticals, Cook Medical Inc., Pantarhei Bioscience B.V., Mayer Laboratories Inc., BioSante Pharmaceuticals Inc., Agile Therapeutics Inc., Pfizer Inc., Allergan, Church & Dwight Co. Inc., Bayer HealthCare AG, Merck & Co, Cryos USA, Mankind Pharma, HRA Pharma, SA, Aurobindo Pharma Limited, Sandoz International GmbH, Gavis Pharmaceuticals (Lupin Limited), Uniprix, Perrigo Company plc, Sun Pharmaceutical Industries Ltd., Actavis Generics (Teva Pharmaceutical Industries Ltd.), Evofem Biosciences Inc., and Abbott Laboratories.
Reasons to buy this Human Reproductive Technologies Market Report
◘ Save time carrying out entry-level research by identifying the size, growth, and leading players in the emerging Human Reproductive Technologies Market
◘ Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the emerging Human Reproductive Technologies Market
◘ Leading company profiles reveal details of key Human Reproductive Technologies Market players emerging five operations and financial performance
◘ Add weight to presentations and pitches by understanding the future growth prospects of the emerging Human Reproductive Technologies Market with five year historical forecasts
◘ Compares data from North America, South America, Asia Pacific Europe and Middle East Africa, alongside individual chapters on each region
The next part also sheds light on the gap between supply and consumption. Apart from the mentioned information, growth rate of Human Reproductive Technologies Market in 2028 is also explained. Additionally, type wise and application wise consumption tables and figures of Human Reproductive Technologies Market are also given.
𝐁𝐮𝐲 𝐓𝐡𝐢𝐬 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐁𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 𝐖𝐢𝐭𝐡 𝐅𝐥𝐚𝐭 𝐔𝐒𝐃 𝟐𝟎𝟎𝟎 𝐎𝐟𝐟 @
https://www.coherentmarketinsights.com/promo/buynow/3921
Table of Content
- Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Technology
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Key Developments
- Technological Advancement
- Regulatory Scenario
- Market Dynamics
- Global Human Reproductive Technologies Market, By Technology, 2017 – 2027 (US$ Mn)
- Introduction
- Market Share Analysis, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, 2019–2027
- Segment Trends
- Infertility Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
- Segment Trends
- Contraceptive Drugs and Devices
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
- Segment Trends
- Introduction
- Global Human Reproductive Technologies Market, By Regions, 2017 – 2027 (US$ Mn)
- Introduction
- Market Share Analysis, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, 2019–2027
- Segment Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
- North Africa
- Central Africa
- South Africa
- Introduction
- Competitive Landscape
- Company Profiles
- Abbott Laboratories
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Evofem Biosciences, Inc.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Actavis Generics (Teva Pharmaceutical Industries Ltd.)
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sun Pharmaceutical Industries Ltd.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Perrigo Company plc
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Uniprix
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Gavis Pharmaceuticals (Lupin Limited)
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sandoz International GmbH
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Aurobindo Pharma Limited
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- HRA Pharma, SA
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Other Major Players
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Abbott Laboratories
- Company Profiles
- Section
- References
- Research Methodology
- About us and Sales Contact
About Coherent Market Insights
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837